Jacqueline L Anderson1, Caitlin Miles2, Audrey C Tierney3. 1. Dietetics and Human Nutrition, School of Allied Health, La Trobe University, Bundoora, Melbourne, Australia. Electronic address: anderson.jl@latrobe.edu.au. 2. Nutrition and Dietetics, Monash Health, Clayton, Victoria, Australia. 3. Dietetics and Human Nutrition, School of Allied Health, La Trobe University, Bundoora, Melbourne, Australia; Department of Nutrition and Dietetics, Alfred Health, Prahran, Melbourne, Australia.
Abstract
BACKGROUND: An increasing body of research investigating the use of probiotics to improve health outcomes in patients with cystic fibrosis (CF) prompted the need to systematically assess and summarise the relevant literature. METHODS: An electronic search of five databases and three trial databases was conducted. Studies describing the administration of probiotics to patients with CF older than 2years, with a comparator group on respiratory, gastrointestinal and nutritional outcomes were included. RESULTS: Three pre-post studies and six randomised controlled trials met the inclusion criteria. Overall studies showed a positive effect of probiotics on reducing the number of pulmonary exacerbations and decreasing gastrointestinal inflammation. There was limited effect of probiotics on other outcomes and inadequate evidence for the effects of specific probiotic species and strains. CONCLUSION: The findings suggest that probiotics may improve respiratory and gastrointestinal outcomes in a stable CF clinic population with no reported evidence of harm. There is inadequate evidence at this time to recommend a specific species, strain or dose of probiotic as likely to be of significant benefit.
BACKGROUND: An increasing body of research investigating the use of probiotics to improve health outcomes in patients with cystic fibrosis (CF) prompted the need to systematically assess and summarise the relevant literature. METHODS: An electronic search of five databases and three trial databases was conducted. Studies describing the administration of probiotics to patients with CF older than 2years, with a comparator group on respiratory, gastrointestinal and nutritional outcomes were included. RESULTS: Three pre-post studies and six randomised controlled trials met the inclusion criteria. Overall studies showed a positive effect of probiotics on reducing the number of pulmonary exacerbations and decreasing gastrointestinal inflammation. There was limited effect of probiotics on other outcomes and inadequate evidence for the effects of specific probiotic species and strains. CONCLUSION: The findings suggest that probiotics may improve respiratory and gastrointestinal outcomes in a stable CF clinic population with no reported evidence of harm. There is inadequate evidence at this time to recommend a specific species, strain or dose of probiotic as likely to be of significant benefit.
Authors: Katherine M Antosca; Diana A Chernikova; Courtney E Price; Kathryn L Ruoff; Kewei Li; Margaret F Guill; Natalie R Sontag; Hilary G Morrison; Shuyu Hao; Mitchell L Drumm; Todd A MacKenzie; Dana B Dorman; Lynn M Feenan; Molly A Williams; John Dessaint; Irene H Yuan; Brian J Aldrich; Lisa A Moulton; Lily Ting; Ana Martinez-Del Campo; Edward J Stewart; Margaret R Karagas; George A O'Toole; Juliette C Madan Journal: J Bacteriol Date: 2019-07-24 Impact factor: 3.490
Authors: D G Burke; F Fouhy; M J Harrison; M C Rea; P D Cotter; O O'Sullivan; C Stanton; C Hill; F Shanahan; B J Plant; R P Ross Journal: BMC Microbiol Date: 2017-03-09 Impact factor: 3.605
Authors: Michael J Coffey; Ivan Low; Sacha Stelzer-Braid; Bernd Wemheuer; Millie Garg; Torsten Thomas; Adam Jaffe; William D Rawlinson; Chee Y Ooi Journal: PLoS One Date: 2020-05-22 Impact factor: 3.240
Authors: Michael J Coffey; Isabelle R McKay; Michael Doumit; Sandra Chuang; Susan Adams; Sacha Stelzer-Braid; Shafagh A Waters; Nadine A Kasparian; Torsten Thomas; Adam Jaffe; Tamarah Katz; Chee Y Ooi Journal: BMJ Open Date: 2020-04-14 Impact factor: 2.692